Unlocking the potential of
genomic medicine

2017 News Releases

Date Title
Toggle Summary12/15/2016
PHILADELPHIA , Dec. 15, 2016 /PRNewswire/ --  Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc.  Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language which means "life story" and reflects the
Toggle Summary11/22/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/22/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 30, 2016 at 11:00 AM EST at the
Toggle Summary11/09/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/09/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference in London, UK on Thursday, November 17, 2016 at 10:40 a.m.
Toggle Summary11/03/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/03/16 -- Medgenics, Inc. (NASDAQ: MDGN) Presented Data Confirming Prevalence of Genetic Mutations in Pediatric ADHD at the 63 rd Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting Began Trading on the NASDAQ Global Markets Medgenics,
Toggle Summary10/29/2016
PHILADELPHIA , Oct. 29, 2016 /PRNewswire/ -- Medgenics, Inc. (NASDAQ: MDGN) – New data presented at AACAP's 63 rd Annual Meeting ( Oct. 24-29, 2016 in New York, NY ) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).  The
Toggle Summary10/26/2016
PHILADELPHIA, PA -- (Marketwired) -- 10/26/16 -- Medgenics, Inc. (NASDAQ: MDGN) will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results for the third quarter ended September 30, 2016 and discuss recent business updates.
Toggle Summary10/10/2016
PHILADELPHIA, PA -- (Marketwired) -- 10/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) (the "Company") announced today that it has been approved for listing on the NASDAQ Global Market , continuing to trade under the symbol "MDGN." Trading on the NASDAQ Global Market is expected to commence on October
Toggle Summary09/06/2016
PHILADELPHIA, PA -- (Marketwired) -- 09/06/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Monday, September 12, 2016 at 9:10
Toggle Summary08/04/2016
PHILADELPHIA, PA -- (Marketwired) -- 08/04/16 -- Medgenics, Inc. (NYSE MKT: MDGN) Initiated Phase 2/3 study of lead program in mGluR+ ADHD Entered into collaboration for second pediatric product in Inflammatory Bowel Disease Strengthened balance sheet with successful financing Medgenics, Inc.
Toggle Summary07/27/2016
PHILADELPHIA, PA -- (Marketwired) -- 07/27/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Thursday, August 4, 2016 at 8:30 a.m. EDT to report financial results for the second quarter ended June 30, 2016 and discuss recent business updates.